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Abstract: Over the past four or five decades, there has been increasing interest in the 
neurochemical regulation of cognition. This field received considerable attention in the 
1980s, with the identification of possible cognition enhancing agents or “smart drugs”. 
Even  though  many  of  the  optimistic  claims  for  some  agents  have  proven  premature, 
evidence suggests that several metabolic agents may prove to be effective in improving and 
preserving  cognitive  performance  and  may  lead  to  better  cognitive  aging  through  the 
lifespan. Aging is characterized by a progressive deterioration in physiological functions 
and  metabolic  processes.  There  are  a  number  of  agents  with  the  potential  to  improve 
metabolic  activity.  Research  is  now  beginning  to  identify  these  various  agents  and 
delineate their potential usefulness for improving cognition in health and disease. This 
review  provides  a  brief  overview  of  the  metabolic  agents  glucose,  oxygen,  pyruvate, 
creatine, and L-carnitine and their beneficial effects on cognitive function. These agents are 
directly  responsible  for  generating  ATP  (adenosine  triphosphate)  the  main  cellular 
currency of energy. The brain is the most metabolically active organ in the body and as 
such is particularly vulnerable to disruption of energy resources. Therefore interventions 
that  sustain  adenosine  triphosphate  (ATP)  levels  may  have  importance  for  improving 
neuronal dysfunction and loss. Moreover, recently, it has been observed that environmental 
conditions and diet can affect transgenerational gene expression via epigenetic mechanisms. 
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Metabolic  agents  might  play  a  role  in  regulation  of  nutritional  epigenetic  effects.  In 
summary,  the  reviewed  metabolic  agents  represent  a  promising  strategy  for  improving 
cognitive function and possibly slowing or preventing cognitive decline.  
Keywords:  metabolic  agents;  glucose;  oxygen;  pyruvate;  creatine;  L-carnitine;  
cognition; ageing 
 
1. Energy Metabolism and Impairments 
For  all biological  and  molecular events and  for multiple cellular functions, energy is  essential. 
Energy is available in the form of the cellular energy-carrying molecule ATP (adenosine triphosphate), 
most of which is generated through aerobic cellular respiration of carbohydrate and glucose, the major 
source  of  biological  free  energy  in  higher  organisms.  Reduced  energy  levels  threaten  cellular 
homeostasis  and  integrity.  Impaired  energy  metabolism  may  trigger  pro-apoptotic  signaling 
(programmed cell death), oxidative damage, excitotoxicity and impede mitochondrial DNA repair [1]. 
These processes can interact and potentiate one another which in turn results in a continuation of 
energy  depletion.  At  the  cellular  level,  depletion  of  ATP  (the  molecular  unit  of  currency  of 
intracellular energy transfer) causes neuron depolarisation leading to failure of membrane ion-transport 
systems. Calcium influx then leads to the release of neurotransmitters, including high quantities of 
glutamate, which then activates N-methyl-D-aspartate (NMDA) and other excitatory receptors on other 
neurons. Depolarisation of these neurones causes further exacerbation of calcium influx and further 
glutamate release. As these processes potentiate one another neuronal insult is amplified. The large 
calcium influx also activates degenerative enzymes which destroy cell membranes and other neuronal 
structures. Oxidants such arachidonic acid, and nitric oxide are produced by this process leading to 
further  neuronal  damage.  Mitochondria  provide  energy  for  basic  metabolic  processes,  produce 
oxidants as inevitable by products, and decay with age impairing cellular metabolism and leading to 
cellular  decline.  Mitochondrial  membrane  potential,  respiratory  control  ratio,  and  cellular  oxygen 
consumption decline with age and oxidant production increases [2]. Mitochondrial decay may be the 
principal underlying event in aging [3–5]. During normal aging neuronal cell injury and death are 
accelerated and lead to region specific brain shrinkage. In brain regions particularly important for the 
formation of memories and decision making, e.g., the hippocampus and the prefrontal cortex/white 
matter, shrinkage increases with age [6]. Reduction in the total number of viable cells may lead to an 
accelerated  decline  in  brain  functioning.  Furthermore  a  number  of  diseases  and  disorders  where 
cognitive impairments are evident co-present with metabolic impairment and neuronal cell loss such as 
Parkinson’s disease, Huntingtons disease, Alzheimer’s disease and amyotrophic lateral sclerosis [7] as 
well  as  mental  disorders  such  as  depression  [8],  schizophrenia  [9],  and  bipolar  disorder  [10]. 
Consequently, there has been increasing interest in exploring the use of metabolic agents in combating 
cognitive  decline.  Interventions  which  improve  mitochondrial  function  by  sustaining  adenosine 
triphosphate (ATP) levels may have substantial importance for improving neuronal dysfunction and 
loss.  Therefore  regimes  that  buffer  intracellular  energy  levels  may  impede  the  progression  of Nutrients 2011, 3  
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neurodegeneration. In the following sections we will provide a brief overview of the metabolic agents 
glucose, oxygen, pyruvate, creatine, and L-carnitine and their beneficial effects on cognitive function. 
2. Metabolic Agents 
2.1. Glucose and Oxygen 
All living cells store useful energy in the compound ATP. Glucose is one of the most abundant 
sugars  in  our  diet,  representing  80%  of  the  final  products  of  carbohydrate  digestion.  Whilst 
representing  only  2%  of  the  total  body  weight,  the  brain  accounts  for  20–30%  of  total  basal 
metabolism [11] with approximately 120 g of glucose being oxidised by the brain daily [12]. Glucose 
is either broken down to power the  formation  of ATP (glycolysis) or  stored as long polymers of 
glucose molecules, e.g., glycogen (glycogenesis). During aerobic (in the presence of oxygen) cellular 
respiration, the process of glycolysis yields pyruvate. Pyruvate is then transformed to an acetyl group 
during transition reaction. The acetyl group is used in the Krebs cycle (Krebs cycle or the tricarboxylic 
acid cycle) and the phase ends with ATP being released in the electron transport chain within the 
mitochondria. Anaerobic (in the absence of oxygen) respiration/fermentation in human muscle cells is 
the enzymatic conversion of pyruvate to lactate with lactate dehydrogenase (LDH) which produces 
ATP in the Embden Meyerhoff pathway [13].  
Beyond  infancy,  and  under  normal  conditions,  the  brains  energy  requirements  are  met  almost 
exclusively by the breakdown of glucose. During times of hypoglycaemia other tissues will cease to 
utilize glucose all together in order to increase glucose availability to the brain [14]. Compared to other 
organs in the body the brain is particularly vulnerable to small and transient changes in its energy 
supply. Interrupted delivery leads within seconds to unconsciousness and within minutes may cause 
irreparable brain damage. Thus the concentration of glucose in the blood plasma is tightly regulated to 
stay within the normal range of 60 to 90 mg/100 mL for humans. When blood glucose drops below  
40  mg/100  mL  (hypoglycemic  condition)  in  humans,  it  can  cause  discomfort,  confusion,  coma, 
convulsions, or even death [15]. 
Compared with other organs the brain possesses paradoxically limited stores of glycogen, which 
without  replenishment  are  exhausted  in  up  to  10  min.  In  nervous  tissue,  glycogen  is  stored  in 
astrocytes. Astrocytes participate significantly in brain glucose uptake and metabolism and due to their 
location and metabolic versatility they may be the “fuel processing plants” within the central nervous 
system [15]. Glucose deprivation in astroglial cultures results in reduction in the ATP/ADP ratio and 
membrane depolarization [16] or rapid depletion of glycogen stores [17]. Moreover, cell death results 
if concentrations of intracellular ATP have fallen within 30 to 48 h to very low levels (lower than  
10% of the initial value). Of particular interest to the current review paper is that animal research has 
shown that inhibition of glycogenolysis in astrocytes can impair memory consolidation [18]. Blood 
glucose concentrations above the normal range (hyperglycemic condition) can also have damaging 
physiological effects. Because glucose exerts osmotic pressure in the extracellular fluid, extremely 
high blood glucose concentrations can cause cellular dehydration. An excessively high level of blood 
glucose concentration also causes loss of glucose in the urine, which can affect kidney function and 
deplete the body’s supply of fluids and electrolytes [19]. Nutrients 2011, 3  
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According to Love and Webb [20], the brain uses approximately twenty percent of the body’s blood 
and  needs  twenty-five  percent  of  the  body’s  oxygen  supply  to  function  optimally.  Associated 
measurements of oxygen and glucose levels in blood sampled upon entering and leaving the brain in 
humans show that almost all the oxygen utilized by the brain can be accounted for by the oxidative 
metabolism of glucose [21]. While the storage capacity of glucose in the brain is very limited, no 
storage capacity for oxygen exists in the brain thus cerebral hypoxia (reduced supply of oxygen to the 
brain) or anoxia (complete lack of oxygen to the brain) leads to almost instantaneous effects on brain 
function. Since the brain is clearly susceptible to small changes in energy supply, brain function is 
highly dependent on the availability and metabolism of glucose and oxygen resources. 
2.1.1. Glucose and Cognitive Function 
The role of glucose in the modulation of cognitive processes is well established. Beneficial effects 
of glucose administration have been observed across different populations using different experimental 
paradigms. For example, previous research has demonstrated that glucose administration can enhance 
learning and memory in healthy young and aged animals and humans (see for example [22–28]) and 
may  improve  several  cognitive  functions  in  subjects  with  severe  cognitive  pathologies,  including 
individuals with Alzheimer’s disease [29,30] and Down’s syndrome [31]. Facilitation of cognitive 
performance induced by elevations in plasma glucose levels have also been reported in patients with 
schizophrenia [32,33]. Furthermore, impairments in certain cognitive skills have been recognized as a 
possible  complication  of  long-standing  non-insulin  and  insulin  dependent  diabetes  mellitus,  and 
evidence  exists  that  improved  glycemic  control  can  ameliorate  performance  on  selective  areas  of 
cognition in these populations [34,35]. Although, benefits in cognitive performance have been found in 
a range of cognitive tasks, converging evidence across populations and methodologies suggest that 
glucose has most pronounced effects on memory performance [19]. 
As  with  many  drugs  affecting  cognitive  performance,  glucose  displays  an  inverted  U-shaped  
dose-response curve, and its effect is time dependent [36,37]. For young adults 25 g seems to most 
reliably facilitate cognitive performance however there is some evidence suggesting that the optimal 
dose may be dependent upon age, inter-individual difference in glucose metabolism and the cognitive 
domain being assessed [37]. The clearest enhancement effects of increased glucose supply have been 
observed for verbal declarative memory in a variety of conditions and paradigms [38]. These findings 
have led to the notion that glucose facilitation may be particularly pronounced in tasks which pertain to 
the  hippocampal  formation,  which  is  strongly  involved  in  declarative  memory  [39].  A  further 
mediating factor for cognitive enhancement by increased glucose availability appears to be the level of 
task demand. That is, tasks which are more cognitively demanding appear to be more sensitive to the 
effect  of  glucose  loading  [40–42].  Also,  the  data  indicates  that  possible  “depletion”  of  episodic 
memory capacity and/or glucose resources in the brain due to performing a concomitant cognitive task 
might be crucial to the demonstration of a glucose facilitation effect. Although the exact underlying 
mechanisms  for  this  are  still  unclear,  animal  research  has  demonstrated  selective  reduction  in 
extracellular hippocampal glucose concentrations as a function of the cognitive demand associated 
with different memory tasks [43]. Moreover, lowered peripheral glucose levels following performance 
of a cognitively demanding task have been reported [44]. Nutrients 2011, 3  
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2.1.2. Oxygen and Cognitive Function 
It is commonly accepted that oxygen restriction and ischemic deprivation exert marked effects on 
cognitive function [45]. The global anterograde amnesia resulting from acute hypoxic brain injury due 
to  cardiac  or  respiratory  arrest  has  also  been  documented.  Clinically,  post-hypoxic  chronic  global 
amnesia resembles the types of amnesia associated with: bilateral thalamic infarction, Korsakoff’s 
syndrome, herpes encephalitis and bilateral temporal lobe resection [45]. In addition to non-localised 
effects, localised lesion patterns can also occur  following brain hypoxia. For example, using PET 
(positron  emission  tomography),  Volpe  and  Hirst  [46]  showed  that  following  brain  hypoxia,  the 
regional cerebral metabolic rate of glucose consumption was significantly below normal limits in the 
thalamus and the medial temporal cortex. These data suggests that post-hypoxic amnesia derives from 
damage  to  the  medial  temporal  cortex  and  its  thalamic  projection  areas.  However,  even  transient 
oxygen  deprivation  leads  to  functional  but  reversible  deficits  [47,48].  Oxygen  administration  is 
capable of reversing the effects of hypoxia with a small therapeutic window, e.g., cognitive deficits 
from  oxygen  restriction  due  to  altitude  [49],  carbon  monoxide  poisoning  [50]  and  isovolemic 
anemia [51]  can  all  be  reversed  by  oxygen  administration.  However  impairment  effects  may  be 
permanent if treatment is not administered in time. 
Analogous  to  the  findings  that  deficit  in  glucose  regulation  and  utilization,  due  to  age,  may 
contribute  to  memory  impairments  in  elderly  people;  age-related  cognitive  decline  has  also  been 
attributed to impaired delivery of oxygen through the cerebral vasculature [52,53]. With age, cortical 
blood supply is reduced to up to 30% [54,55] and additional reduction of regional and total blood flow 
can be observed in patients with memory impairments [56,57]. Early research by Edwards and Hart 
examining  the  effects  of  hyperbaric  oxygen  supplementation  demonstrated  improved  cognitive 
function  (short-term  memory  and  visual  organization)  in  elderly  outpatients  compared  to  baseline 
performance. However this study failed to compare with a control group [58]. This study showed 
significant improvements in mean Wechsler intelligence quotients in elderly participants, who were 
given 15 daily 2-h sessions of hyperbaric oxygenation. However, other studies showed no reversal of 
age-related cognitive impairments following normobaric or hypobaric oxygen treatment [59]. 
Only few studies have investigated the  effect of oxygen administration on cognition in normal 
healthy  individuals.  In  the  late  1970s,  Walker  and  Sandman  [60]  provided  indirect  evidence  that 
relatively small fluctuations in cerebral oxygen delivery can influence cognitive performance. They 
investigated the effect of tachistoscopic digit presentation during the various cycles of cardiac output 
on stimulus processing and EEG parameters. Their results showed that stimuli presented during the 
P wave (immediately prior to systolic contraction of the heart) were perceived more accurately than 
those during the T wave (at the end of the contraction). More recently a series of studies investigating 
the effects of oxygen administration in young healthy adults showed that it led to improved long term 
memory and reaction times compared to a control group (normal air-breathing) [61–63]. Furthermore, 
similar to glucose facilitation, oxygen administration appears to facilitate cognition most effectively 
for  tasks  with  a  higher  cognitive  load  [61,62].  A  further  study  also  examined  heart  rate  during 
cognitive  testing  with  oxygen  versus  air-breathing  controls.  Compared  to  baseline,  heart  rate  was 
significantly elevated during cognitive testing tasks in both the air and oxygen groups. In the oxygen 
group,  significant  correlations  were  found  between  changes  in  oxygen  saturation  and  cognitive Nutrients 2011, 3  
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performance.  In  the  air  group,  greater  changes  in  heart  rate  were  associated  with  more  improved 
cognitive performance [64]. These findings suggest that during times of cognitive demand availability 
of metabolic resources impact on cognitive functioning. A more recent study has further demonstrated 
the importance of metabolic resources during cognitive demand by manipulating level of cognitive 
demand during oxygen administration. In this study oxygen administration of 40% versus 21% was 
examined during completion of an addition task with three levels of difficulty. It was observed that 
40% oxygen improved accuracy scores across the task compared to the 21% oxygen dose, with the 
difference in accuracy rate increasing between the two dosages as the task difficulty level increased [65]. 
While  cognitive  demand  is  clearly  a  moderating  factor  for  cognitive  enhancement  by  oxygen, 
enhancement has been observed on several cognitive domains for example oxygen supplementation 
has been shown to improve everyday memory tasks such as memory for shopping lists and putting 
names to faces when participants received 100% oxygen compared with air-breathing controls [66].  
The  dose  response  for  oxygen  administration  on  performance  appears  to  follow  the  inverted  
U-shaped function which has also been observed to describe the relationship between level of arousal 
and performance on certain tasks [67] with the most effective doses being one and three minutes for 
immediate and delayed word recall, and 30 s for tests of attention while continuous oxygen breathing 
for longer than 10 min leads to decline in performance [61]. The window for cognitive improvement 
through oxygen administration therefore appears to be quite brief, with research demonstrating that 
administration of oxygen increases blood oxygen levels for only 4–5 min [61]. In summary, these 
findings indicate that small increases in the availability of the metabolic substrate oxygen may improve 
cognitive function. 
2.2. Pyruvate 
Neuronal cell death resulting from hypoglycemia and hypoxia is the result of a series of events 
triggered by reduced energy availability, and the normalization of blood glucose and oxygen levels 
does not necessarily block or reverse this cell death process once it has begun. During times of low 
availability of glucose and oxygen the brain utilizes other, less efficient energy sources that can be 
produced aerobically. Pyruvate is the end product of glycolysis, which is converted into acetyl CoA 
that enters the Krebs cycle when there is sufficient oxygen available. When the oxygen is insufficient, 
pyruvate is broken down anaerobically, creating lactate in humans and animals. Lactate has recently 
been considered as a central neuroprotective agent [68]. The blood-brain barrier normally transports 
pyruvate at a rate much slower than glucose, but prior work suggests that significant pyruvate entry to 
the brain can be achieved by elevating plasma pyruvate concentrations [69]. 
2.2.1. Pyruvate and Neuroprotection 
During pathological insult or general aging the main upstream event most responsible for neuronal 
cell death is excitotoxicity from glutamate receptor activity [70]. Recent research has shown that cells 
that  would  otherwise  die  after  the  cascade  of  excitototic  activity  could  be  rescued  by  providing 
pyruvate  [71].  One  recent  study  assessed  the  effect  of  pyruvate  administration  in  rats  with 
hypoglycaemia-induced brain injury. Insulin was used to induce hypoglycaemia and then terminated 
through (i) glucose administration, and (ii) combined glucose and pyruvate administration. The results Nutrients 2011, 3  
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of the study showed that in the four brain regions studied (CA1, subiculum, dentate gyrus of the 
hippocampus, and piriform cortex) combined glucose and pyruvate administration led to a reduction in 
neuronal death by 70–90%. Increased neuronal survival was also observed when pyruvate delivery was 
delayed for up to 3 h. The improved neuron survival was accompanied by a sustained improvement in 
cognitive function as assessed by the Morris water maze [72].  
Since pyruvate appears to be most beneficial in times of low glucose supply recent research has 
evaluated the potential usefulness for ethyl pyruvate as a stroke therapy using a rat cerebral ischemia 
model of middle cerebral artery occlusion. Cerebral ischemia leads to brain injury through a complex 
series of pathophysiological events leading to neuronal death and subsequent neurological dysfunction. 
In addition the data suggest that this acute neuronal damage is followed by a second round of neuronal 
injury, called delayed neuronal death, in the neighbouring areas of the ischemic core [73]. Yu et al. [74] 
found that ethyl pyruvate affords strong protection against the delayed cerebral ischemic injury with 
significant reduction in infarct volume accompanied by the suppression of the clinical manifestations 
associated with cerebral ischemia, including motor impairment and neurological deficits. 
2.2.2. Pyruvate and Cognitive Function 
There  is  remarkably  little  research  evaluating  the  effects  of  pyruvate  on  cognitive  function. 
However evidence from pre-clinical research has shown that pyruvate infused into the medial septum 
is capable of reversing the memory-impairing action of morphine [75] and hippocampal infusion has 
demonstrated  reversal  of  the  memory-impairing  effects  of  septal  muscimol  (a  GABAA  receptor 
agonist)  [76].  Mild  hypoglycemic  conditions  in  rat  hippocampal  slices  interfere  with  long-term 
potentiation  (LTP)  induction  [77]  and  it  has  been  demonstrated  that  when  glucose  is  unavailable, 
pyruvate is capable of promoting LTP in CA1 region of rat hippocampal slices [78].  
There are, as yet, no studies evaluating the effects of pyruvate administration on cognitive function 
in humans, however pvruvate may be a good candidate for further research in those with energetic 
depletion  and  neurodegenerative  diseases.  Impaired  energy  metabolism  is  an  early,  predominant 
feature in Alzheimer’s disease and it is believed that impaired cerebral oxidative glucose metabolism is 
responsible, at least in part, for cognitive impairment in AD. Impairment in glucose utilization in the 
CNS has been proposed as a possible cause of dementia in Alzheimer’s disease [79]. Research has 
demonstrated that in both animals and humans increased cerebrospinal pvruvate is a biomarker for 
AD [80,81]  and  a  significant  reduction  of  pyruvate  dehydrogenase  (the  enzyme  responsible  for 
transformation of pyruvate into acetyl-CoA by  pyruvate decarboxylation for use in the  citric  acid 
cycle) in post mortem AD brain. Since pyruvate administration appears to be quite safe, aside from 
mild side effects, such as occasional stomach upset and diarrhea, pyruvate therapy might represent an 
excellent candidate for therapy in disease states with co-morbidity of energetic dysfunction. 
2.3. Creatine 
Creatine (Cr) is a naturally occurring nitrogenous organic acid found in vertebrates. Cr participates 
in metabolic reactions within cells and eventually is catabolized in the muscles creating creatinine 
which  is  then  excreted  by  the  kidney  in  urine.  In  the  averaged  sized  adult  (70  kg),  Cr  store  is 
approximately 120 g, with the daily turnover of Cr to creatinine being estimated to be about 1.6% of Nutrients 2011, 3  
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the bodies total Cr [82]. The daily requirement of Cr either through diet or endogenous synthesis is 
suggested to be approximately 2 g/day [83]. A single 5 g oral dose in healthy adults results in a peak 
plasma Cr level of approximately 120 mg/L at 1–2 h post-ingestion. The elimination half life of Cr is 
quite short (just less than 3 h), however elevated plasma levels can be maintained by loading small oral 
doses every 3–6 h (12–24 g total per day) throughout the day. After a period of loading (1–2 weeks) it 
is no longer necessary to maintain a consistently high serum level of Cr since there is a maximum 
tissue storage capacity, with excess being eliminated as waste [84–86]. Dietary sources of Cr are fish 
and  red  meat  [82]  therefore  Cr  levels  of  vegetarian  or  vegan  individuals  tend  to  be  much  lower  
than  omnivores.  Cr  derived  from  the  diet,  after  passing  through  the  intestinal  lumen,  enters  the  
bloodstream intact [87] with an average of around 0.25–1 g of Cr per day being obtained from a 
typical omnivorous diet.  
When Cr is being stored, it is converted to the high energy form of phosphocreatine (PCr) which 
acts as a high-energy reserve in a coupled reaction in which energy derived from donating phosphate is 
used to regenerate the compound ATP. In the brain ATP is tightly coupled with Cr and PCr levels 
within  the  cell.  During  times  of  brain  activity  brain  phospocreatine  decrease  rapidly  in  order  to 
maintain constant ATP levels [88,89]. Furthermore, in vivo research examining total Cr in the brain, 
using  quantitative  localized  proton  magnetic  resonance  spectroscopy,  have  demonstrated  that 
supplementation (2 g per day over 1 month) leads to increases in overall mean concentration of Cr in 
the brain (8.7%) with region dependent increases [90,91]. 
2.3.1. Creatine and Neuroprotection 
Since Cr is a critical component of maintaining cellular energy homeostasis research has examined 
its potential neuroprotective effects in various models of neurological disease. Animal research has 
shown  that  Cr  is  particularly  important  for  normal  brain  development  and  function.  For  example 
depletion of cytosolic brain-type creatine kinase in mice has been shown to result in slower learning of 
a spatial task and diminished open-field habituation and creatine kinase B-driven energy transfer in  
the  brain  is  important  for  mossy  fibre  field  size  and  determination  of  seizure  susceptibility  [92].  
Pre-clinical  trials  have  shown  that  in  rats  and  mice  Cr  affords  significant  neuroprotection  against 
ischemic and oxidative insults [93–95]. One experiment investigated the possible effect of Cr dietary 
supplementation  on  brain  tissue  damage  after  experimental  traumatic  brain  injury.  Results 
demonstrated that chronic administration of Cr ameliorated the extent of cortical damage by as much 
as 36% in mice and 50% in rats. The authors suggested that protection is mediated by Cr-induced 
maintenance of mitochondrial bioenergetics as they observed that mitochondrial membrane potential 
was significantly increased, intra-mitochondrial levels of reactive oxygen species and calcium were 
significantly decreased, and adenosine triphosphate levels were maintained. Induction of mitochondrial 
permeability transition was significantly inhibited in animals fed Cr [96].  
Cr may be a good candidate as a neuroprotective agent against acute and delayed neurodegenerative 
processes. In rodents Cr has been shown to attenuate neurodegenerative symptoms. For example rats 
administered 3-nitropropionic acid (3NP) display neuropathological and behavioral abnormalities that 
are analogous to those observed in Huntington’s disease (HD). Rats fed diets containing 1% Cr over an 
8 week  period  showed  attenuation  of  3NP-induced  striatal  lesions,  striatal  atrophy,  ventricular Nutrients 2011, 3  
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enlargement, cognitive deficits, and motor abnormalities on a balance beam task compared to non-Cr 
supplemented  rats.  These  findings  indicate  that  Cr  provides  significant  protection  against 
neuropathological insult specifically associated with 3NP-induced behavioral and neuropathological 
abnormalities [97]. An in depth review of the neuroprotective role of Cr is beyond the scope of this 
review, however a detailed and comprehensive appraisal of the use of creatine in Huntington’s disease, 
Parkinson’s disease, amyotrophic lateral sclerosis, Alzheimer’s disease as well as spinal cord injury, 
stroke and epilepsy can be found in “Creatine and Creatine Kinase in Health and Disease—A Bright 
Future Ahead?” [98]. 
2.3.2. Creatine and Cognitive Function 
Despite the obvious impact Cr has on brain development and metabolic actions in the brain there 
are relatively few studies assessing the effects of Cr on cognitive performance in humans. Clinical 
trials assessing the effects of Cr on cognitive function can be divided into semi-acute administration 
protocols (periods of between 5–7 days) and more chronic administration protocols (administration for 
6  weeks+).  No  research  has  yet  examined  the  acute  effects  of  Cr  on  cognitive  function  over  the 
ensuing  hours  following  administration.  Furthermore  the  majority  of  this  research  has  focused  on 
young healthy adult samples. Cr administration appears to facilitate mood and cognitive function most 
robustly during times of low energy or fatigue. For example one study examined the effect of 20 g Cr 
supplementation over 7 days in sleep deprived individuals (24 h sleep deprivation). Individuals who 
received Cr supplementation demonstrated significantly attenuated performance on a number of tasks 
including  random  movement  generation,  choice  reaction  time,  balance  and  mood  state  [99].  In  a 
further  study  following  36  h  sleep  deprivation,  Cr  supplemented  individuals  also  demonstrated 
improved performance on a random number generation task [100]. One study assessed the effects of  
8 g Cr per day for 5 days in healthy individuals and demonstrated attenuation of mental fatigue when 
subjects repeatedly performed a simple mathematical calculation. In addition, task-evoked increase of 
cerebral oxygenated haemoglobin was significantly reduced following Cr supplementation, indicating 
increased oxygen utilization in the brain [101]. A more recent study assessed the impact of a new form 
of creatine, creatine ethyl ester, over a 2 week period (5 g per day dose compared to dextrose control 
group)  in  healthy  18–24  year  old  participants.  The  overall  findings  demonstrated  consistent 
improvements for reaction times across a range of measures as well as improved memory and IQ 
scores. The strongest improvements appeared to be on tasks that were more cognitively demanding, 
indicating  that  creatine  supplementation  may  be  particularly  useful  when  performing  particularly 
demanding or complex cognitive tasks [102].  
Interestingly, to date chronic administration studies appear to show less evidence for improved 
cognitive performance. For example, following administration of 0.03 g/kg per day for 6 weeks, no 
effect was observed in healthy young adults on a range of cognitive and psychomotor task (including 
measures  of  reaction  time,  reasoning,  information  processing  and  memory)  [103].  However, 
populations who only produce Cr endogenously appear to benefit from additional Cr administration 
Daily administration of 5 g of Cr (Cr monohydrate) for 6 weeks led to significant positive effects on 
both  working  memory  (backward  digit  span)  and  intellectual  efficiency  (Raven’s  Advanced 
Progressive Matrices) in a sample of 45 young vegetarian adults [104].  Nutrients 2011, 3  
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Since glucose and oxygen are the primary fuel for brain function it is reasonable that other fuel 
sources and modes of producing ATP are utilized during times of low energy availability or high 
energy demands. This preference of energy utilization appears to be reflected in the Cr literature. In 
that  cognition  is  ameliorated  or  attenuated  specifically  during  times  of  metabolic  impairment  or 
depletion, either through low creatine availability (vegan and vegetarian samples) or by inducement 
(sleep deprivation or high cognitive demand). Since elderly populations are generally metabolically 
impaired and often nutritionally deficient, it seems likely that this population would most benefit from 
creatine interventions over time. To our knowledge only one study has assessed the impact of Cr 
supplementation in an elderly human population. McMorris et al. administered 20 g of Cr per day for 
7 days and found improved performance in a number of cognitive tasks including random number 
generation, numeric and spatial working memory tasks, and long-term memory tasks [105]. To date 
there has been no research examining the effects of creatine supplementation in dementia sufferers, 
however  there  appears  to  be  some  differences  in  creatine  levels  in  those  with  genetic  risk  of 
developing  dementia  (apolipoprotein  ε4  carriers).  Laakso  et  al.  demonstrated  that  compared  with  
non-carriers, the levels of creatine were significantly lower in ε4 carriers. This finding may suggest 
increased metabolic demands in the brain of the ε4 carriers. They also observed that the levels of 
creatine correlated significantly with age and performance on the Mini-Mental State Examination test 
in the ε4 carriers, but not in the non-carriers [106].  
Although  research  to  date  indicates  that  creatine  supplementation  might  have  the  potential  to 
ameliorate or ward off cognitive decline in some populations to a certain extend, there is still a great 
deal of research to be done in this area and a number of questions which remain to be answered. Firstly 
there has been no research examining whether an acute administration of one single dose of Cr can 
affect cognitive performance. Secondly since there is some evidence that creatine supplementation 
improves  cognitive  function  in  young,  healthy  non  vegetarian  individuals  over  shorter  periods  of 
administration (5 days–2 weeks) but not over longer periods (6 weeks+). Therefore it is possible that 
adaptation or tolerance on a neuronal metabolic or other physiological level may take place following 
a certain period of time. Thus further research is required in order to establish optimal dose of Cr and 
inasmuch optimal dose changes in sub-chronic administration regimes. Moreover, there is a clear lack 
of investigations into its benefits in populations with mild or marked cognitive impairments. To date 
only one study has examined the effects in the elderly and no study has been carried out using patients 
with  dementia.  Since  the  evidence  suggests  that  Cr  acts  to  buffer  intracellular  energy  levels  and 
potentially hamper the progression of neurodegenerative processes a more systematic evaluation of Cr 
mapping cognitive performance over a longer timeframe is required. 
2.4. L-Carnitine/Acetyl-L-Carnitine 
In animals and humans, carnitine is biosynthesized primarily in the liver and kidneys from the 
amino acids lysine or methionine [107] with Vitamin C (ascorbic acid) being essential to the synthesis 
of carnitine. In food the highest concentrations of carnitine are found in red meat and dairy products. 
Other natural sources of carnitine include nuts and seeds, legumes or pulses, vegetables and cereals. 
Carnitine exists in two stereoisomers: Its biologically active form is L-carnitine, while its enantiomer, 
D-carnitine, is biologically inactive [108]. Carnitine transports long-chain acyl groups from fatty acids Nutrients 2011, 3  
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into the mitochondrial matrix, so that they can be broken down through β-oxidation to acetate to obtain 
usable energy via the citric acid cycle. Under normal nutritional conditions and in healthy persons,  
L-carnitine  availability  is  not  a  limiting  step  in  β-oxidation;  however  L-carnitine  is  required  for 
mitochondrial  long-chain  fatty  acid  oxidation  [109],  which  is  a  main  source  of  energy  during  
exercise  [110].  Furthermore  increase  in  L-carnitine  content  might  increase  the  rate  of  fatty  acid 
oxidation,  permitting  a  reduction  of  glucose  utilization,  preserving  muscle  glycogen  content,  and 
ensuring  maximal  rates  of  oxidative  ATP  production.  In  one  study  L-carnitine  improved  glucose 
disposal among 15 patients with type II diabetes and 20 healthy volunteers [111]. Glucose storage 
increased between both groups and glucose oxidation increased in the diabetic group. Furthermore 
glucose uptake increased by approximately 8% for both diabetic and non-diabetic groups.  
In  neuronal  cells,  the  L-carnitine  shuttle  mediates  translocation  of  the  acetyl  moiety  from 
mitochondria  into  the  cytosol  and  contributes  to  the  synthesis  of  acetylcholine  and  of  
acetylcarnitine [112,113]. The neurobiological effects of acetyl carnitine include modulation of brain 
energy  and  phospholipids  metabolism,  cellular  macromolecules  (such  neurotrophic  factors  and 
neurohormones), synaptic morphology, and synaptic transmission of multiple neurotransmitters [114]. 
2.4.1. L-Carnitine/Acetyl-L-Carnitine and Neuroprotection 
A number of studies have examined neuroprotective effects of L-carnitine and acetyl L-carnitine 
treatment in vitro. For example acetyl L-carnitine has been shown to reduce cell mortality in primary 
cell cultures from rat hippocampal formation and cerebral cortex of 17-day-old rat embryos when cell 
mortality is induced by 24 h foetal calf serum deprivation. Furthermore, acetyl L-carnitine also protected 
against exposure to glutamate and kainic. Moreover the neurotoxity induced by N-methyl-D-aspartate 
was attenuated by the acute co-exposure with acetyl L-carnitine. Cell mortality was also investigated in 
hippocampal cultures chronically treated with β-amyloid fragment in which acetyl  L-carnitine also 
demonstrated neuroprotective activity [115]. Furthermore Ishii and colleagues demonstrated that both 
acetyl L-carnitine and L-carnitine administration to primary cultured neurons from the cerebral cortex, 
striatum  and  thalamus  of  18-day-old  rat  embryos,  deprived  of  serum,  promoted  neuronal  survival 
(from apoptosis) and mitochondrial activity in a concentration-dependent manner [116]. 
Pre-clinical in vivo research has also demonstrated neuroprotective action of L-carnitine in the rat 
model  of  3-nitropropionic  acid  (3-NPA)-induced  mitochondrial  dysfunction.  3-NPA  is  known  to 
produce decreases in neuronal ATP levels via inhibition of the succinate dehydrogenase at complex II 
of the mitochondrial electron transport chain. Succinate dehydrogenase is involved in reactions of the 
Krebs cycle and oxidative phosphorylation, and its inhibition leads to both necrosis and apoptosis. It 
was  observed  that  pre-treatment  with  L-carnitine  totally  prevented  the  3-NPA-induced  decrease  in 
brain temperature. The authors suggest that the protective effects of L-carnitine against 3-NPA-induced 
neurotoxicity  are  achieved  via  compensatory  enhancement  of  several  pathways  of  mitochondrial 
energy metabolism [117]. L-carnitine has also been shown to prevent hypoglycemia-induced neuronal 
damage  in  the  hippocampus,  by  preserving  mitochondrial  functions  [118].  Acetyl  L-carnitine  also 
appears to be effective at promoting neurologic recovery from experimental focal cerebral ischemia in 
rats [119] and complete, global cerebral ischemia in dogs [120].  Nutrients 2011, 3  
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2.4.2. L-Carnitine/Acetyl-L-Carnitine and Cognition 
The  majority  of  research  assessing  the  effects  of  L-carnitine  or  acetyl-L-carnitine  (acetylated 
derivative of  L-carnitine with improved bioavailability) have focused on its benefits to elderly and 
populations  with  dementia.  Acetly  L-carnitine  transverses  the  blood  brain  barrier  efficiently,  and 
sufficient  increase  in  CSF  concentrations  following  oral  and  intravenous  administration  has  been 
observed in patients with severe dementia [121]. In terms of efficacy, a meta-analysis examining the 
effects of acetyl-L-carnitine in mild cognitive impairment and mild (early) Alzheimer’s disease was 
conducted [122]. Studies included in the analysis were at least 3 months in duration, with a dosage of 
between 1.5–3.0 g/day. The results showed beneficial effects on both clinical scales and psychometric 
tests  with  improvements  after  3  months  and  even  stronger  enhancements  with  longer  treatment 
regimes. In a more recent study the effects of 2 g of  L-carnitine daily for 6 days was assessed in 
centenarians  [123]  and  those  treated  with  L-carnitine  demonstrated  significant  physiological 
improvements  in  fat  mass,  muscle  mass,  plasma  total  carnitine  and  plasma  long  and  short-chain 
acetylcarnatine. They also showed significantly less mental fatigue and improved cognitive function 
assessed by the Mini-Mental State Examination (MMSE).  
There are, as yet, no studies examining the effect of L-carnitine or acetyl-L-carnitine on cognitive 
function in young human populations. Since the action of L-carnitine availability is not a limiting step 
in β-oxidation any beneficial effects are most likely to be observed in populations with depleted energy 
resources or under physically fatigued conditions. Therefore the utility of L-Carnitine/acetyl-L-carnitine 
may be more pronounced in age and degenerative disease, however healthy young populations might 
benefit in physically demanding and stressful situations.  
3. Underlying Mechanisms 
Metabolic  agents  might  represent  a  simple  intervention  for  improving  and  maintaining  optimal 
cognitive performance across the life-span. In terms of the underlying mechanisms, these agents are 
directly responsible for generating ATP, the main cellular currency of energy. The brain is the most 
metabolically active organ in the body and as such is particularly vulnerable to disruption of energy 
resources. Consequently, the cognition enhancing and neuroprotective effects of these agents might be 
due to their ability to optimize coordination between ATP consumption and ATP production processes 
and  therefore  minimizing  metabolite  gradients,  reducing  energy  dissipation  and  providing  optimal 
metabolic energy supplies according to physiological needs. However, the most likely scenario is that 
the underlying mechanisms are likely to be multifarious and not necessarily restricted to provision of 
energy  necessary  for  optimal  cell  function.  Recently,  it  has  been  observed  that  diet  can  affect 
transgenerational  gene  expression  via  “reversible”  heritable  epigenetic  mechanisms.  Epigenetic 
marking on genes can determine whether or not genes are expressed. Among the different mechanisms 
that could lead to interindividual differences in cognitive ageing and neurodegeneration, the epigenetic 
regulation of gene expression might be an important contributor. Nutritional, chemical and physical 
factors have been shown to influence epigenetic events and thereby modifying gene expression profile 
and  disease  risk  [124].  Although  the  degree  of  epigenetic  plasticity  changes  across  the  life  span, 
epigenetic  changes  occur  at  all  stages  of  life  and  accumulate  over  time.  For  example,  maximal Nutrients 2011, 3  
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differences in DNA methylation profile have been observed in aged monozygotic twins with a history 
of non-shared environments [125–127]. 
Determinants of gene expressions include DNA methylation and intake of meythyl donors (such as 
choline, methionine, zinc, betaine and folate) might alter gene expression, but also macronutrients and 
more general agents that alter ATP-dependent complexes [128]. Since it has been shown that diets 
and/or nutritional compounds which affect energy metabolism can have global epigenetic effects [129], 
prevention and therapy of cognitive impairments and neurodegenerative processes by diets aimed at 
optimising bio-availability of metabolic agents present an exciting prospect. Metabolic agents might 
play a role in regulation of nutritional epigenetic effects, which in turn might account for their benefits 
on cognition.  
4. Summary and Implications 
Research is now beginning to identify various agents which may impact on metabolic functioning 
and delineate their potential usefulness for improving cognition in health and disease. Glucose and 
oxygen are the primary sources of fuel for the brain and body and thus received the most extensive 
research attention in terms of their effects on cognitive function. As a result, the optimal dosage, time 
frame  and  conditions  of  administration  to  reveal  facilitation  of  cognition  are  becoming  better 
delineated. However the limitations of supplementation of these substrates are also becoming clear and 
translation into therapeutic interventions is likely to be varied. Oxygen has a very small therapeutic 
window while glucose supplementation does not represent a viable strategy for neuro-enhancement 
over any prolonged timeframe since consistently elevated blood glucose leads to insulin resistance. 
However, therapeutic and nutritional interventions aimed at maintenance of optimal blood glucose 
regulation are important target candidates. Moreover, other substrates reviewed here include pyruvate, 
creatine and L-carnitine. These metabolic agents have received less attention in the field of cognition 
research and subsequently their potential efficacy as cognitive enhancers and neuroprotectants still 
requires  much  work.  However,  the  evidence  reviewed  here  provides  a  promising  basis  for  future 
research. Mediation of cognitive function by metabolic agents appears to be most robustly observed in 
those  individuals  with  some  metabolic  impairment  or  low  energy  availability.  Future  research  of 
metabolic agents for cognitive function could be divided into three main areas: (i) optimising cognitive 
function in young healthy individuals, (ii) neuroprotection form cognitive decline and (iii) clinical 
samples with either central or co-morbid metabolic impairment. It is clear that in normal young healthy 
adults cognition can be altered by even small metabolic fluctuations and that metabolic impairment as 
a result of aging or disease is associated cognitive decline. Therefore interventions which improve 
metabolic function or prop up ATP production may have a vast number of implications in health and 
disease.  Finally,  the  potential  role  of  the  reviewed  agents  as  epigenetic  modulators  clearly  merits 
further research.  
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